SG11202008343YA - IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE - Google Patents
IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFEInfo
- Publication number
- SG11202008343YA SG11202008343YA SG11202008343YA SG11202008343YA SG11202008343YA SG 11202008343Y A SG11202008343Y A SG 11202008343YA SG 11202008343Y A SG11202008343Y A SG 11202008343YA SG 11202008343Y A SG11202008343Y A SG 11202008343YA SG 11202008343Y A SG11202008343Y A SG 11202008343YA
- Authority
- SG
- Singapore
- Prior art keywords
- igm
- affect
- life
- serum half
- chain mutations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862637186P | 2018-03-01 | 2018-03-01 | |
PCT/US2019/020374 WO2019169314A1 (en) | 2018-03-01 | 2019-03-01 | IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202008343YA true SG11202008343YA (en) | 2020-09-29 |
Family
ID=67805543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008343YA SG11202008343YA (en) | 2018-03-01 | 2019-03-01 | IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE |
Country Status (12)
Country | Link |
---|---|
US (2) | US10899835B2 (en) |
EP (1) | EP3758752A4 (en) |
JP (2) | JP7376490B2 (en) |
KR (1) | KR20200128391A (en) |
CN (1) | CN111787951A (en) |
AU (1) | AU2019227984A1 (en) |
BR (1) | BR112020017296A2 (en) |
CA (1) | CA3091144A1 (en) |
IL (1) | IL276590A (en) |
MX (1) | MX2020009069A (en) |
SG (1) | SG11202008343YA (en) |
WO (1) | WO2019169314A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3105250T3 (en) | 2014-02-10 | 2020-09-28 | Igm Biosciences Inc | MULTISPECIFIC IGA BINDING MOLECULES |
BR112016022841B1 (en) | 2014-04-03 | 2023-09-26 | Igm Biosciences, Inc | IGM, IGA, IGG/IGM OR IGG/IGA ANTIBODY COMPRISING A MODIFIED CHAIN |
CN107207601A (en) | 2015-01-20 | 2017-09-26 | Igm生物科学股份有限公司 | TNF (TNF) superfamily receptors binding molecule and its application |
KR20220018081A (en) | 2015-03-04 | 2022-02-14 | 아이쥐엠 바이오사이언스 인코포레이티드 | Cd20 binding molecules and uses thereof |
US10604559B2 (en) | 2015-03-25 | 2020-03-31 | Igm Biosciences, Inc. | Multi-valent hepatitis B virus antigen binding molecules and uses thereof |
JP6811723B2 (en) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | Multivalent human immunodeficiency virus antigen-binding molecule and its usage |
JP7065766B2 (en) | 2015-09-30 | 2022-05-12 | アイジーエム バイオサイエンシズ インコーポレイテッド | Bonded molecule with modified J chain |
EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
JP6979971B2 (en) | 2016-05-09 | 2021-12-15 | アイジーエム バイオサイエンシズ インコーポレイテッド | Anti-PD-L1 antibody |
SG11201908051RA (en) | 2017-04-07 | 2019-09-27 | Igm Biosciences Inc | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
JP7376490B2 (en) | 2018-03-01 | 2023-11-08 | アイジーエム バイオサイエンシズ インコーポレイテッド | IgM Fc and J chain mutations affecting IgM serum half-life |
AU2020334882A1 (en) * | 2019-08-17 | 2022-02-24 | Igm Biosciences, Inc. | Multimeric bispecific anti-CD123 binding molecules and uses thereof |
CN110669134A (en) * | 2019-10-15 | 2020-01-10 | 广东菲鹏生物有限公司 | IgM-FC fragment, IgM-FC antibody, preparation method and application |
US20230073926A1 (en) * | 2020-01-06 | 2023-03-09 | Igm Biosciences, Inc. | Highly sialylated multimeric binding molecules |
KR20230005228A (en) | 2020-04-22 | 2023-01-09 | 아이쥐엠 바이오사이언스 인코포레이티드 | PD-1 agonist multimeric binding molecule |
IL297619A (en) * | 2020-05-12 | 2022-12-01 | Igm Biosciences Inc | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer |
US20220033851A1 (en) * | 2020-08-03 | 2022-02-03 | Roger B. Swartz | mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A. |
WO2022080912A1 (en) * | 2020-10-16 | 2022-04-21 | 주식회사 아이엠바이오로직스 | Fusion protein platform using igm region |
WO2023064766A1 (en) * | 2021-10-11 | 2023-04-20 | Igm Biosciences, Inc. | Lateral flow device and uses thereof |
WO2023196995A1 (en) | 2022-04-07 | 2023-10-12 | Repertoire Immune Medicines, Inc. | T cell receptor multimers and uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6045774A (en) * | 1997-01-10 | 2000-04-04 | Epicyte Pharmaceutical Inc. | J chain polypeptide targeting molecule linked to an imaging agent |
CA2276046A1 (en) | 1997-01-10 | 1998-07-16 | Epicyte Pharmaceutical, Inc. | Novel epithelial tissue targeting agent |
US20050129616A1 (en) | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20040248299A1 (en) | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
AU2005304973A1 (en) | 2004-11-05 | 2006-05-18 | Palingen, Inc. | Antibody induced cell membrane wounding |
US20070111281A1 (en) * | 2005-05-09 | 2007-05-17 | Glycart Biotechnology Ag | Antigen binding molecules having modified Fc regions and altered binding to Fc receptors |
EP2313502A4 (en) | 2008-07-14 | 2012-04-04 | Uchicago Argonne Llc | Methods for systematic control of protein stability |
ES2672121T3 (en) * | 2009-10-07 | 2018-06-12 | Macrogenics, Inc. | Polypeptides containing Fc region that have an enhanced effector function due to alterations in the degree of fucosylation, and methods for their use |
JP6335796B2 (en) | 2012-02-08 | 2018-06-06 | アイジーエム バイオサイエンシズ インク.Igm Biosciences Inc. | CDIM binding protein and use thereof |
BR112015021341B1 (en) | 2013-03-15 | 2023-03-28 | Dana-Farber Cancer Institute Inc. | ISOLATED HUMANIZED FLAVIVIRUS NEUTRALIZING MONOCLONAL ANTIBODIES AND THERAPEUTIC USES THEREOF |
WO2015053887A1 (en) | 2013-09-05 | 2015-04-16 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
DK3105250T3 (en) | 2014-02-10 | 2020-09-28 | Igm Biosciences Inc | MULTISPECIFIC IGA BINDING MOLECULES |
BR112016022841B1 (en) | 2014-04-03 | 2023-09-26 | Igm Biosciences, Inc | IGM, IGA, IGG/IGM OR IGG/IGA ANTIBODY COMPRISING A MODIFIED CHAIN |
CN107207601A (en) | 2015-01-20 | 2017-09-26 | Igm生物科学股份有限公司 | TNF (TNF) superfamily receptors binding molecule and its application |
KR20220018081A (en) | 2015-03-04 | 2022-02-14 | 아이쥐엠 바이오사이언스 인코포레이티드 | Cd20 binding molecules and uses thereof |
US10604559B2 (en) | 2015-03-25 | 2020-03-31 | Igm Biosciences, Inc. | Multi-valent hepatitis B virus antigen binding molecules and uses thereof |
JP6811723B2 (en) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | Multivalent human immunodeficiency virus antigen-binding molecule and its usage |
EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
JP7065766B2 (en) * | 2015-09-30 | 2022-05-12 | アイジーエム バイオサイエンシズ インコーポレイテッド | Bonded molecule with modified J chain |
JP6979971B2 (en) | 2016-05-09 | 2021-12-15 | アイジーエム バイオサイエンシズ インコーポレイテッド | Anti-PD-L1 antibody |
US20190330374A1 (en) | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
CA3030659A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
EP3496536A4 (en) | 2016-07-20 | 2020-02-12 | IGM Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
CA3030634A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
SG11201908051RA (en) | 2017-04-07 | 2019-09-27 | Igm Biosciences Inc | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
US20200392239A1 (en) | 2018-02-26 | 2020-12-17 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
JP7376490B2 (en) | 2018-03-01 | 2023-11-08 | アイジーエム バイオサイエンシズ インコーポレイテッド | IgM Fc and J chain mutations affecting IgM serum half-life |
AU2019368289A1 (en) * | 2018-10-23 | 2021-04-29 | Igm Biosciences, Inc. | Multivalent IgM- and IgA-Fc-based binding molecules |
WO2020163646A1 (en) * | 2019-02-08 | 2020-08-13 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
-
2019
- 2019-03-01 JP JP2020543995A patent/JP7376490B2/en active Active
- 2019-03-01 EP EP19760662.7A patent/EP3758752A4/en active Pending
- 2019-03-01 AU AU2019227984A patent/AU2019227984A1/en active Pending
- 2019-03-01 SG SG11202008343YA patent/SG11202008343YA/en unknown
- 2019-03-01 CA CA3091144A patent/CA3091144A1/en active Pending
- 2019-03-01 WO PCT/US2019/020374 patent/WO2019169314A1/en active Application Filing
- 2019-03-01 CN CN201980016388.5A patent/CN111787951A/en active Pending
- 2019-03-01 MX MX2020009069A patent/MX2020009069A/en unknown
- 2019-03-01 KR KR1020207023441A patent/KR20200128391A/en not_active Application Discontinuation
- 2019-03-01 BR BR112020017296-0A patent/BR112020017296A2/en unknown
-
2020
- 2020-03-23 US US16/827,100 patent/US10899835B2/en active Active
- 2020-08-09 IL IL276590A patent/IL276590A/en unknown
- 2020-12-03 US US17/110,550 patent/US20210087273A1/en not_active Abandoned
-
2023
- 2023-10-26 JP JP2023183845A patent/JP2024016093A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3091144A1 (en) | 2019-09-06 |
MX2020009069A (en) | 2020-10-08 |
BR112020017296A2 (en) | 2020-12-29 |
US20200239572A1 (en) | 2020-07-30 |
US20210087273A1 (en) | 2021-03-25 |
EP3758752A4 (en) | 2021-12-15 |
US10899835B2 (en) | 2021-01-26 |
CN111787951A (en) | 2020-10-16 |
JP2024016093A (en) | 2024-02-06 |
AU2019227984A1 (en) | 2020-09-10 |
EP3758752A1 (en) | 2021-01-06 |
IL276590A (en) | 2020-09-30 |
JP2021514618A (en) | 2021-06-17 |
KR20200128391A (en) | 2020-11-12 |
JP7376490B2 (en) | 2023-11-08 |
WO2019169314A1 (en) | 2019-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276590A (en) | Igm fc and j-chain mutations that affect igm serum half-life | |
EP3459973A4 (en) | Anti-human pd-l1 humanized monoclonal antibody and application thereof | |
EP3505535A4 (en) | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof | |
IL278920A (en) | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | |
EP3426686A4 (en) | Humanized anti-pacap antibodies and uses thereof | |
EP3466974A4 (en) | Anti-human pd-1 humanized monoclonal antibody and use thereof | |
EP3181587A4 (en) | Anti-human il-17 monoclonal antibody and use thereof | |
EP3464355A4 (en) | Dsg2 monoclonal antibody and use thereof | |
ZA201807132B (en) | Humanized anti-basigin antibodies and the use thereof | |
LT3445785T (en) | Humanized anti clever-1 antibodies and their use | |
EP3841125A4 (en) | Monoclonal antibodies against human tim-3 | |
EP3567053A4 (en) | Anti-claudin-2 monoclonal antibody | |
KR101882087B1 (en) | Monoclonal antibody against viral hemorrhagic septisemia virus and use thereof | |
EP3785732A4 (en) | Antibody against tim-3 and application thereof | |
EP3590964A4 (en) | Improved anti-vegfr-2 monoclonal antibody | |
EP3562507A4 (en) | Anti-human tim-3 antibodies and methods of use thereof | |
EP3901172A4 (en) | Humanized anti-pd-1 antibody and use thereof | |
IL281608A (en) | Anti-human cd45rc antibodies and uses thereof | |
EP3733705A4 (en) | Monoclonal antibodies and methods for using same | |
EP3901171A4 (en) | Anti-human tim-3 monoclonal antibody and application thereof | |
EP3774920A4 (en) | Anti-pd-l1 antibodies and use thereof | |
EP3529274A4 (en) | A monoclonal antibody and a method of use for the treatment of lupus | |
EP3404042A4 (en) | Monoclonal antibody fnab8 and application thereof | |
EP3847192A4 (en) | Monoclonal antibodies against endotrophin and the use thereof | |
GB201911211D0 (en) | Monoclonal antibodies against ambra-1 |